In May, The Scientist, in collaboration with Frost & Sullivan, an international market intelligence and consulting firm, conducted a brief survey of our readers about their use of next-generation sequencing (NGS) technology. The majority of NGS work is focused on disease-related and basic research. While only 40% of respondents perform in-house NGS, that percentage is expected to increase by 4% in the next year. Half of those surveyed plan to perform RNA-Seq in the next two years. The most significant bottleneck in NGS workflow is the length of time spent analyzing and interpreting data, with 32% of the respondents outsourcing the work to in-house bioinformatics colleagues or third-party companies.
—Christi Bird, Senior Industry Analyst, Life Sciences, Frost & Sullivan
All figures are rounded